Premorbid cognitive testing predicts the onset of dementia and Alzheimer's disease better than and independently of APOE genotype

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 75, Issue 8, 2004, Pages 1100-1106

  Cervilla, J ^a   Prince, M ^a   Joels, S ^b   Lovestene, S ^a   Mann, A ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E;

AGE DISTRIBUTION; AGED; ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DEMENTIA; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FAMILY HISTORY; FOLLOW UP; GENOTYPE; HUMAN; HYPERTENSION; LEARNING TEST; MENTAL TASK; MINI MENTAL STATE EXAMINATION; MORBIDITY; NEUROPSYCHOLOGICAL TEST; ONSET AGE; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; SCREENING TEST;

AGED; ALZHEIMER DISEASE; APOLIPOPROTEINS E; COHORT STUDIES; DEMENTIA; FEMALE; GENOTYPE; HUMANS; MALE; MENTAL STATUS SCHEDULE; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TIME FACTORS;

EID: 3442891269     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.2003.028076     Document Type: Article

References (50)

1. Braak H, Braak E. Evolution of neuronal changes in the course of Alzheimer's disease. J Neural Transm 1998;53(suppl):127-40.
2. Palmer K, Backman L, Winglad B, et al. Detection of Alzheimer's disease and dementia in the preclinical phase: population based cohort study. BMJ 2003;326:245-9.
3. Chen P, Ratcliff G, Belle SH, et al. Cognitive tests that best discriminate between presymptomatic AD and those who remain non demented. Neurology 2000;55:1847-53.
4. Elias MF, Beiser A, Wolf PA, et al. The preclinical phase of Alzheimer disease. A 22 year prospective study of the Framingham cohort. Arch Neurol 2000;57:808-13.
5. MRC Working Party. MRC Research Council Trial of treatment of hypertension in older adults: principal results. BMJ 1992;304:405-12.
6. Prince MJ. Predicting the onset of Alzheimer's disease using Bayes' theorem. Am J Epidemiol 1996;143:301-8.
7. Prince MJ, Cullen MC, Mann AH. Risk factors for Alzheimer's disease and dementia: a case-control study based on the MRC Elderly Hypertension Trial. Neurology 1994;44:97-104.
8. Prince M, Lovestone S, Cervilla J, et al. The association between APOE and dementia seems not to be mediated by vascular factors. Neurology 2000;54:397-402.
9. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98.
10. Copeland JRM, Dewey ME, Griffith-Jones HM. A computerised psychiatric diagnostic system and case nomenclature for elderly subjects: GMS and AGECAT. Psychol Med 1986;16:89-99.
11. Roth M, Tym E, Mountjoy CQ, et al. CAMDEX. A standardised instrument for the diagnosis of mental disorder in the elderly with special reference to the early detection of dementia. Br J Psychiatry 1986;149:698-709.
12. Broe GA, Akhtar AJ, Andrews GR, et al. Neurological disorders in the elderly at home. J Neurol Neurosurg Psychiatry 1976;39:361-6.
13. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. Washington DC: AMA, 1994.
14. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-44.
15. Roman GC, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993;43:250-60.
16. Inglis J. A poired-associate learning test for use with elderly psychiatric patients. J Ment Sci 1959;105:440-3.
17. Reltan RM. Validity of the trail making test as an indication of organic brain damage. Percept Motor Skills 1959;8:271-6.
18. Nelson H, O'Connell A, Dementia. The estimation of pre-morbid intelligence levels using the new adult reading test. Cortex 1978;14:234-44.
19. Raven JC. Matrix tests. Mental Health 1940;1:10-18.
20. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982;143:29-36.
21. Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983;148:839-43.
22. Centor RM. A Visicalc program for estimating the area under a receiver operating characteristic (ROC) curve. Med Decis Making 1985;5:139-48.
23. Soininen HS, Scheltens P. Early diagnostic indices for the prevention of Alzheimer's disease. Ann Med 1998;30:553-9.
24. Bowen J, Teri L, Kukull W, et al. Progression to dementia in patients with isolated memory loss. Lancet 1997;349:763-5.
25. Tierney MC, Szalai JP, Snow WG, et al. Prediction of probable Alzheimer's disease in memory-impaired patients: a prospective longitudinal study. Neurology 1996;46:661-5.
26. Masur DM, Fuld PA, Blau AD, et al. Predicting development of dementia in the elderly with the selective reminding test. J Clin Exp Neuropsychol 1990;12:529-38.
27. Chen P, Ratcliff G, Bell S, et al. Cognitive tests that best discriminate between presymptomatic AD and those who remain nondemented. Neurology 2000;55:1847-53.
28. Palmer K, Bäckman L, Winblad B, et al. Detection of Alzheimer's disease and dementia in the preclinical phase: population based cohort study. BMJ 2003;326:245-50.
29. Backman L, Small BJ, Fratiglioni L. Stability of the preclinical episodic memory deficit in Alzheimer's disease. Brain 2001;124:96-102.
30. Deary IJ, Whalley LJ, St Clair D, et al. The influence of the epsilon 4 allele of the apolipoprotein E gene on childhood IQ, nonverbal reasoning in old age, and lifetime cognitive change. Intelligence 2003;31:85-92.
31. Turic D, Fisher PJ, Plomin R, et al. No association between apolipoprotein E polymorphisms and general cognitive ability in children. Neurosci Lett 2001;299:97-100.
32. Deary IJ, Whiteman MC, Pattie A, et al. Cognitive change and the APOE e4 allele. Nature 2002;418:932.
33. Cervilla JA, Prince M, Joels S, et al. Long term determinants of cognitive outcome in a cohort of elderly hypertensives. Br J Psychiatry 2000;177:66-71.
34. Yip AG, Brayne C, Easton D, et al. Apolipoprotein E4 is only a weak predictor of dementia and cognitive decline in the general population. Am J Med Genet 2002;39:639-43.
35. Wilson RS, Schneider JA, Barnes LL, et al. The apolipoprotein E epsilon 4 allele and decline in different cognitive systems during a 6-year period. Arch Neurol 2002;59:1154-60.
36. Prince MJ. Is chronic low-level lead exposure in early life an etiological factor in Alzheimer's disease? Epidemiology 1998;9:618-21.
37. Snowdon DA, Kemper SJ, Mortimer JA, et al. Linguistic ability in early life and cognitive function and Alzheimer's disease in late life. JAMA 1996;275:528-32.
38. Stern Y, Gurland B, Tatemichi TK, et al. Influence of education and occupation on the incidence of Alzheimer's disease. JAMA 1994;271:1004-10.
39. Stern Y, Tang MX, Denaro J, et al. Increased risk of mortality in Alzheimer's disease patients with more advanced educational and occupational attainment. Ann Neurol 1995;37:590-5.
40. Hirono N, Hashimoto M, Yasuda M, et al. The effect of APOE epsilon 4 allele on cerebral glucose metabolism in AD is a function of age at onset. Neurology 2002;58:743-50.
41. Relkin NR, Kwon YJ, Tsai J, et al. The National Institute on Aging/Alzheimer's Association recommendations on the application of apolipoprotein E genotyping to Alzheimer's disease. Ann NY Acad Sci 1996;802:149-76.
42. American College of Medical Genetics/American Society of Human Genetics Working Group on ApoE and Alzheimer disease. Statement on use of apolipoprotein E testing for Alzheimer disease. JAMA 1995;274:1627-9.
43. Jack CR, Petersen RC, Xu Y, et al. Rate of medial temporal lobe atrophy in typical aging and Alzheimer's disease. Neurology 1998;51:993-9.
44. Reiman EM, Uecker A, Caselli RJ, et al. Hippocampal volumes in cognitively normal persons at genetic risk far Alzheimer's disease. Ann Neurol 1998;44:288-91.
45. Bottino CM, Almeida OP. Can neuroimaging techniques identify individuals at risk of developing Alzheimer's disease? Int Psychogeriatr 1997;9:389-403.
46. Andersen K, Launer LJ, Ott A, et al. Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease? The Rotterdam Study. Neurology 1995;45:1441-5.
47. Stewart WF, Kawas C, Corrada M, et al. Risk of Alzheimer's disease and duration of NSAID use. Neurology 1997;48:626-32.
48. Yaffe K, Sawaya G, Lieberburg I, et al. Estrogen therapy in pastmenopausal women: Effects on cognitive function and dementia. JAMA 1998;279:688-95.
49. Asthana S, Baker LD, Craft S, et al. High-dose estradiol improves cognition for women with AD - results of a randomized study. Neurology 2001;57:605-12.
50. Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999;400:116-17.